Protalix BioTherapeutics, Inc. (NYSE: PLX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ... [Yahoo! Finance]
Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results [Yahoo! Finance]
Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results
Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024